ArticleProstate cancer2026
PROK1 Expression Is Associated With Prognosis and May Influence Response to Antiandrogen Therapy in Prostate Cancer.
Article in Prostate cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have found that PROK1 is involved in the progression of tumors. This study aims to investigate the association of PROK1 with prognosis and its potential relationship with the efficacy of antiandrogen therapy in prostate cancer and to explore the underlying mechanisms. Methods: A total of 498 and 1249 prostate cancer samples were obtained from the TCGA and GEO databases, respectively. First, the expression of PROK1 in prostate cancer was analyzed in the bulk RNA sequencing dataset, and the prognostic value of PROK1 was explored. Subsequently, pseudotime analysis and virtual knockout were conducted in the single-cell RNA sequencing dataset to investigate its biological function in tumor progression. Further cell communication analysis revealed the interactions between cells. Additionally, the predictive function and changes of PROK1 expression in antiandrogen therapy were explored through the GDSC database and in vitro experiments. Results: PROK1 was downregulated in prostate cancer and decreased with advancing TNM stage. Meta-analysis also showed lower PROK1 expression in tumor and metastatic prostate cancer compared to controls. Single-cell RNA sequencing analysis suggested that PROK1 was specifically highly expressed in mesenchymal stem cells (MSC)-like stromal cells. Virtual knockout of the PROK1 perturbation analysis revealed that the differentially expressed genes were enriched in insulin-like growth factor receptor signaling pathway. Moreover, PROK1-positive stromal cells had stronger IGFBP signal communication with prostate cancer cells. Additionally, PROK1 and IGFBP7 showed spatial expression colocalization. High PROK1 expression in prostate cancer was associated with higher sensitivity to bicalutamide. However, PROK1 expression decreases after antiandrogen therapy. Conclusion: Low PROK1 expression is associated with worse prognosis and may correlate with reduced antiandrogen therapy efficacy. Downregulation of PROK1 after antiandrogen therapy may be related to the treatment resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.